Paule Valery Joseph

Dr. Paule Valery Joseph

National Institutes of Health (NIH), Bethesda, Maryland, 20892, USA
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Cell Metabolism
Verified
Journal Article
Closed access
Kevin HallKevin Hall
Kevin Hall
AAAlexis Ayuketah
Alexis Ayuketah
RBRobert Brychta
Robert Brychta
HCHongyi Cai
Hongyi Cai
TCThomas Cassimatis
Thomas Cassimatis
MZMegan Zhou
Megan Zhou

1 July 2020 in Neuron
Verified
Journal Article
Closed access
KCKeiland W Cooper
Keiland W Cooper
DBDavid H. Brann
David H. Brann
MFMichael C. Farruggia
Michael C. Farruggia
SBSurabhi Bhutani
Surabhi Bhutani
RPRobert Pellegrino
Robert Pellegrino
Antonella Di PizioAntonella Di Pizio
Antonella Di Pizio

21 January 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Kevin HallKevin Hall
Kevin Hall
JGJuen Guo
Juen Guo
ACAmber Courville
Amber Courville
JBJames Boring
James Boring
RBRobert Brychta
Robert Brychta
SCStephanie T. Chung
Stephanie T. Chung

1 July 2019 in Cell Metabolism
Verified
Journal Article
Closed access
KHKevin D. Hall
Kevin D. Hall
AAAlexis Ayuketah
Alexis Ayuketah
RBRobert Brychta
Robert Brychta
HCHongyi Cai
Hongyi Cai
TCThomas Cassimatis
Thomas Cassimatis
MZMegan Zhou
Megan Zhou

15 March 2024 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
YWYupeng Wang
Yupeng Wang
HTHaibao Tang
Haibao Tang
XWXiyin Wang
Xiyin Wang
YSYing Sun
Ying Sun
Paule Valery JosephPaule Valery Joseph
Paule Valery Joseph
APAndrew Paterson
Andrew Paterson

25 December 2020 in Chemical Senses
Verified
Journal Article
Open access
PDF file
RGRichard C Gerkin
Richard C Gerkin
KOKathrin Ohla
Kathrin Ohla
MVMaria G Veldhuizen
Maria G Veldhuizen
Paule Valery JosephPaule Valery Joseph
Paule Valery Joseph
CKChristine E Kelly
Christine E Kelly
MBMarius Baguma
Marius Baguma
In a preregistered, cross-sectional study, we investigated whether olfactory loss is a reliable predictor of COVID-19 using a crowdsourced questionnaire in 23 languages to assess symptoms in individuals self-reporting recent respiratory illness. We quantified changes in chemosensory abilities during the course of the respiratory illness using 0–100 visual analog scales (VAS) for participants reporting a positive (C19+; n = 4148) or negative (C19−; n = 546) COVID-19 laboratory test outcome. Logistic regression models identified univariate and multivariate predictors of COVID-19 status and post-COVID-19 olfactory recovery. Both C19+ and C19− groups exhibited smell loss, but it was significantly larger in C19+ participants (mean ± SD, C19+: −82.5 ± 27.2 points; C19−: −59.8 ± 37.7). Smell loss during illness was the best predictor of COVID-19 in both univariate and multivariate models (ROC AUC = 0.72). Additional variables provide negligible model improvement. VAS ratings of smell loss were more predictive than binary chemosensory yes/no-questions or other cardinal symptoms (e.g., fever). Olfactory recovery within 40 days of respiratory symptom onset was reported for ~50% of participants and was best predicted by time since respiratory symptom onset. We find that quantified smell loss is the best predictor of COVID-19 amongst those with symptoms of respiratory illness. To aid clinicians and contact tracers in identifying individuals with a high likelihood of having COVID-19, we propose a novel 0–10 scale to screen for recent olfactory loss, the ODoR-19. We find that numeric ratings ≤2 indicate high odds of symptomatic COVID-19 (4 < OR < 10). Once independently validated, this tool could be deployed when viral lab tests are impractical or unavailable.